# TWST earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TWST) · [Earnings tab](https://www.lopjlb.com/stock/TWST?tab=earnings)

Updated: 2026-08-03T05:26:10

Quarters analyzed: 8

## Cross-quarter narrative

Across eight earnings calls from Q3 2024 to Q2 2026 Twist Bioscience consistently posted record revenue, but the pace of growth decelerated from a 28% YoY rise in Q3 2024 to roughly 17‑19% by late‑2025 and early‑2026. Gross margin improved markedly, climbing from 43.3% to a peak of 53.4% in Q3 2025 before stabilizing around 51‑52% in 2025‑26, reflecting volume leverage and automation. The company’s adjusted‑EBITDA breakeven target slipped from FY2025 to FY2026, remaining at risk in multiple quarters. Demand for Express Genes, NGS, synthetic‑biology and biopharma services stayed strong, though analysts flagged order‑momentum concerns tied to a large SynBio customer and the lag in biopharma revenue recognition. Capital allocation stayed modest, emphasizing profitability, R&D on proprietary enzymes, and the Atlas DNA‑data‑storage spin‑out. Milestones such as Multiplexed Gene Fragments, Express Antibodies, and several automation upgrades were delivered, while newer initiatives like the Atlas spin‑out and MRD Express launch remain open. Persistent fears include order‑momentum, profitability pressure, cost‑management and competitive dynamics; geopolitical and governance concerns surfaced early and did not reappear later.

## Latest CallCard · Q2

Twist Biosciences posted 19% YoY revenue growth to $110.7M in FQ2'26, driven by 28% DNA/Protein growth from AI discovery and 12% NGS growth; gross margin 51.6%, on track for adj. EBITDA breakeven in Q4.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management emphasized consistent execution, 13th quarte

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q2:** Twist Biosciences posted 19% YoY revenue growth to $110.7M in FQ2'26, driven by 28% DNA/Protein growth from AI discovery and 12% NGS growth; gross margin 51.6%, on track for adj. EBITDA breakeven in Q4.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management emphasized consistent execution, 13th quarte
- **2026 Q1:** —
- **2025 Q4:** Twist reports record Q4 $99M (17% YoY), FY2025 $376.6M (20% YoY), gross margin 51.3%, targets adj. EBITDA breakeven by end FY2026, MRD Express launch early 2026.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize record revenue, 11th consecutive growth quarter, gross margin expansi
- **2025 Q3:** Twist Bioscience reports record Q3 revenue of $96.1M (+18% YoY) and gross margin of 53.4%, narrows FY25 revenue guidance to $374-376M, highlights SynBio underlying growth >20% ex-large customer, NGS +27% driven by clinical assays, and path to adjusted EBITDA breakeven in FY26.','tone': {'mgmt': 0.8,
- **2025 Q2:** Twist posted record Q2 revenue and margin, spun out its DNA data‑storage unit Atlas, and reaffirmed guidance while noting strong demand across NGS, SynBio and academic segments.
- **2025 Q1:** —
- **2024 Q4:** Twist Bioscience posted a record Q4 with revenue up 27% YoY to $84.7M, gross margin 45.1% beating guidance, strong cash $276.4M, and highlighted the Express portfolio and automation driving margin while targeting adjusted EBITDA breakeven in FY25.
- **2024 Q3:** Twist Bioscience posted a record Q3 with 28% revenue growth, 43.3% gross margin and new product launches, while noting a single large customer’s Q4 order dip and ongoing focus on profitability.

## Theme arcs

- **Revenue Growth Rate** (deteriorating): YoY growth fell from ~28% in Q3 2024 to ~17‑19% by Q4 2025‑Q2 2026
- **Gross Margin** (improving): Margin rose from 43.3% to >53% then stabilized around 51‑52%
- **Adjusted EBITDA Breakeven Timeline** (deteriorating): Target moved from FY2025 to FY2026 and remains at risk
- **Demand Visibility** (stable): Strong demand for Express, NGS, SynBio and biopharma services persisted
- **Capital Allocation** (stable): Focus on profitability, modest capex, R&D and Atlas spin‑out
- **Competitive Landscape** (deteriorating): Competitive pressure noted repeatedly as a risk to margins
- **Governance/Related Party Risk** (resolved): Related‑party disclosure risk mentioned in Q4 2024 but not later

## Fear persistence

- **Order momentum / large customer dip** [recurring]: Raised in Q3 2024 and again in Q3 2025
- **Profitability / EBITDA loss** [recurring]: Repeated concern from Q3 2024 through Q2 2026
- **Geopolitical headwinds** [resolved]: Mentioned only in Q3 2024
- **Revenue recognition lag** [resolved]: Highlighted in Q4 2024 only
- **Cost management / inflationary OpEx** [recurring]: Noted in Q4 2024 and Q2 2025
- **R&D execution risk** [recurring]: Appeared in Q4 2024 and Q2 2025
- **Competitive pressure** [recurring]: Cited in Q4 2024 and Q2 2025
- **Revenue growth sustainability (academic budget, tariffs)** [new]: Introduced in Q2 2025
- **Atlas execution risk** [new]: First mentioned with Atlas spin‑out in Q2 2025
- **Academic budget constraints** [new]: Raised in Q2 2025

## Guidance path

2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:vague → 2026 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/TWST`